5326372025-04-012025-06-305326372025-04-012025-06-30in-capmkt:OtherExpenses1Member5326372025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326372025-04-012025-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532637MANGALAMNOTLISTEDINE584F01014MANGALAM DRUGS AND ORGANICS LIMITEDMain BoardEquity2025-04-012026-03-312025-08-072025-07-30INRLakhsQuarterlyFirst quarterSingle segmentBulk manufacturing of Drugs2025-08-0716:00:002025-08-0719:30:00Declaration of unmodified opinion2025-04-012025-06-30UnauditedConsolidated57348700040005734910002333370000162453000938100004044600044757000128671000703474000-1299830000-1299830000800000080000000-1379830000000-137983000-1142000-1391250000000158282480000010-8.72-8.7200-8.72-8.72 1. The above financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act, 2013 read together with Companies (Indian Accounting Standard) Rules 2015 and relevant amendment rules thereafter. <BR> 2. The above un-audited Consolidated financial results of the Company for the Quarter ended have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors of the Company (Mangalam Drug and Organics Limited) at their meeting held on 7th August 2025. <BR> 3. The Company's business activity falls within a single reportable Business Segment Viz. Manufacturing of Bulk Drugs. <BR> 4. The figures for the quarter ended 31st March 2025 are the balancing figures between the audited figures in respect of full financial year upto 31st March 2025 and the unaudited published year- to- date figures upto 31st December 2024 being the date of end of the third quarter of the financial year respectively whichever subjected to limited review. <BR> 5. Consoildated results includes results of Managalm Laboratories Private Limited subsidiary for the purpose of Consolidated results. The wholly owned subsidiary is not material subsidiary of the Company on acquision. <BR> <BR> 6.Other Expenses <BR> Rs. in Lakhs <BR> Sr.No. Particulars Quarter Ended Year Ended <BR> 30.06.2025 31.03.2025 30.06.2024 31.03.2025 <BR> 1 Power & Fuel Expenses 446.44 662.83 611.03 2788.76 <BR> 2 Pollution Control Expenses 168.30 269.30 223.03 901.14 <BR> <BR> 7.The Board of Directors of the Company at its meeting held on 18th June 2024 had considered and approved the scheme of Merger by Absorption of Mangalam Laboratories Private Limited (First Transferor Company) and Shri JB Pharma Private Limited (Formerly known as Shri JB Pharma LLP) (Second Transferor Company) with Mangalam Drugs and Organics Limited (Transferee Company) and their respective shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act 2013. The Scheme is subject to approval of Honarable National Company Law Tribunal. Tribunal has convened meeting for the shareholders and creditor <BR> <BR> 8.The figures for the previous periods have been regrouped wherever necessary to confirm to the current periods under presentation <BR> <BR> Other Expenses128671000Other comprehensive income [Abstract]-1142000-114200000-1142000UnauditedfalseV . S. SOMANI and Co.true2027-07-31